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Abstract
Dynamin plays an essential role in maintaining the structure and function of the glomerular filtration barrier.
Specifically, dynamin regulates the actin cytoskeleton and the turnover of nephrin in podocytes, and knocking
down dynamin expression causes proteinuria. Moreover, promoting dynamin oligomerization with Bis-T-23 restores
podocyte function and reduces proteinuria in several animal models of chronic kidney disease. Thus, dynamin is
a promising therapeutic target for treating chronic kidney disease. Here, we investigated the pathophysiological
role of dynamin under proteinuric circumstances in a rat model and in humans. We found that glomerular Dnm2
and Dnm1 mRNA levels are increased prior to the onset of proteinuria in a rat model of spontaneous proteinuria.
Also, in zebrafish embryos, we confirm that knocking down dynamin translation results in proteinuria. Finally, we
show that the glomerular expression of dynamin and cathepsin L protein is increased in several human proteinuric
kidney diseases. We propose that the increased expression of glomerular dynamin reflects an exhausted attempt
to maintain and/or restore integrity of the glomerular filtration barrier. These results confirm that dynamin plays
an important role in maintaining the glomerular filtration barrier, and they support the notion that dynamin is a
promising therapeutic target in proteinuric kidney disease.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Chronic kidney disease (CKD) is a major health issue
worldwide [1]. The progression of CKD is accompanied
by a reduction in the glomerular filtration rate and sub-
sequent proteinuria. In order to develop new therapeutic
strategies for CKD, it is important to understand the
mechanisms and processes that underlie glomerular fil-
tration. The glomerular filtration barrier (GFB) consists
of several components, including the interdigitating foot
processes of podocytes, the glomerular basement mem-
brane, and a glycocalyx-covered fenestrated endothe-
lium. Disrupting the GFB allows the passage of proteins
into the urinary space. Under normal conditions, these
proteins are then reabsorbed by proximal tubular epithe-
lial cells; however, if the reabsorption mechanism is
impaired or saturated, proteinuria can develop.
Dynamin is a recently identified protein that plays an
important role in maintaining GFB integrity. This
96 kDa GTPase is expressed both in glomerular
podocytes and in tubular epithelial cells [2,3]. Within
the GFB, dynamin has three identified functions: (1)
dynamin is involved in the turnover of nephrin [4];
(2) it interacts directly with actin and actin-regulatory
proteins [5]; and (3) it is involved in the endocytosis of
albumin by podocytes [6]. Several groups have reported
that loss of dynamin using a genetic knockdown model
or via cleavage with the endopeptidase cathepsin L
results in proteinuria [3,4,7]. Moreover, Schiffer et al
demonstrated that dynamin is a potential therapeutic
target in CKD [7]. Specifically, the authors reported
beneficial effects of treating several animal models of
proteinuria with Bis-T-23, a small molecule compound
that stimulates the oligomerization of dynamin to form
a 72-subunit helical structure [8]. Importantly, Schiffer
et al found that administering Bis-T-23 restored the
ultrastructure of podocyte foot processes, decreased
proteinuria, lowered mesangial collagen IV deposition,
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reduced mesangial matrix expansion, and prolonged
survival [7]. Ono et al also showed that Bis-T-23
treatment prevented albuminuria and attenuated alter-
ations in foot process formation in an experimental
mouse model [9]. Although these studies indicate that
dynamin plays an important role in maintaining GFB
structure and function, the majority of this research
relied on the observation of morphological and/or
functional changes in the kidney after genetic manip-
ulation or other alterations in dynamin. Thus, intrinsic
changes in dynamin expression under proteinuric con-
ditions have not been investigated in animal models
or patients.
Here, we report that dynamin expression is increased
in proteinuric conditions. We show that glomerular
Dnm2 and Dnm1 mRNA levels are increased in a rat
model of spontaneous proteinuria prior to the onset of
proteinuria. We also show that knocking down dynamin
translation in a zebrafish embryo model results in
proteinuria. Lastly, we show that glomerular dynamin
and cathepsin L protein levels are increased in human
patients with proteinuric kidney disease.
Materials and methods
Microarray analysis
We analyzed microarray datasets of Dahl and SHR
rats in order to identify differentially regulated
cytoskeleton-related genes. The datasets were retrieved
from the Gene Expression Omnibus of the NCBI,
which is accessible using the GEO Series accession
number GSE 13810. This analysis was performed using
Affymetrix GeneChip Rat Genome 230 2.0 arrays
(Thermo Fisher Scientific, Waltham, MA, USA). Path-
way analysis was performed using the Gene Ontology
Tree Machine (Oak Ridge National Laboratory, Oak
Ridge, TN, USA) and by global testing in the Kyoto
Encyclopedia of Genes and Genomes (Kanehisa Lab-
oratories, Kyoto, Japan) in order to determine which
differentially regulated genes are involved in cytoskele-
tal regulation [10,11]. This microarray was performed
on glomeruli obtained from animals at 4 and 6 weeks of
age (Table 1).
The micro array data analyzed in this study have been
deposited in NCBI’s Gene Expression Omnibus and
are accessible through GEO Series accession number
GSE 13810 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE13810).
Animal studies: rats
The rat experiments were approved by the Institutional
Ethics Committee for Animal Care and Experi-
mentation. Male spontaneously proteinuric Dahl
salt-sensitive rats (Dahl) and non-proteinuric spon-
taneously hypertensive rats (SHR) were obtained
from the Charité-University Medicine Berlin [12].
To prevent the early accelerated development of severe
hypertension, the rats were fed a low-salt diet containing
0.2% NaCl by weight content. Tissues were collected
from animals at 2, 4, 6, 8, and 10 weeks of age. A total
of 67 animals were used, with respectively seven, seven,
seven, eight, and eight Dahl rats per age group and five,
four, six, seven, and eight SHR rats per age group. In
each animal, the left kidney was used to isolate the
glomeruli using magnetic retraction; these samples
were used for mRNA analysis [13]. The right kidney
of each animal was extracted; part was embedded in
paraffin wax, and another part was snap-frozen and
stored −80∘C.
RNA isolation, reverse transcription, and qPCR
RNA was isolated from rat glomeruli using TRIzol
(Invitrogen, Waltham, MA, USA). AMV reverse tran-
scriptase (Roche Diagnostics, Risch-Rotkreuz, Switzer-
land) was used to reverse-transcribe the RNA into
first-strand cDNA,whichwas then analyzed using qPCR
with the primer pairs listed in Table 2.Hprt1was used as
an internal control. qPCR was performed on an iCycler
real-time PCR machine with SYBR Green Supermix
(Bio-Rad Laboratories, Hercules, CA, USA), and iCy-
cler IQ 3.1 software (Bio-Rad Laboratories) was used
to analyze gene expression and to normalize the data.
Dnm1 and Dnm2 mRNA levels are shown as relative
to the average Dnm1 or Dnm2 mRNA expression in
SHR rats.
Animal studies: zebrafish
All zebrafish experiments were performed prior to the
free-feeding embryo stage and are therefore not consid-
ered animal experiments in accordance with the EUAni-
mal Protection Directive 2010/63/EU. Wild-type (WT)
AB/TL strain zebrafish (Danio rerio H) were main-
tained using previously defined standards [14]. Embryos
were obtained through natural crossings and kept in E3
medium at 28.5∘C. In the one- to four-cell stage, the
embryos were injected with 1 nl of a morpholino (Gene
Tools, Philomath, OR, USA) targeting the dnm2 gene (to
knockdown mRNA translation) or a scrambled control
morpholino [15].
Glomerular permeability and tubular reabsorption
assay
A previously validated tubular dextran reabsorp-
tion model was used to assess glomerular per-
meability in zebrafish embryos [16,17]. At 4 days
post-fertilization (dpf), a group of WT embryos were
injected with 3 nl of puromycin aminonucleoside (PAN,
25mg/ml; Sigma-Aldrich, St Louis, MO, USA) to
induce kidney damage as a positive control for pro-
teinuria [17]. At 5 dpf, all groups were injected with
3 nl of a mixture of TRITC-labeled 3 kDa dextran
(100mg/ml; Invitrogen) and FITC-labeled 70-kDa dex-
tran (25mg/ml; Invitrogen). One hour after injection,
the animals were fixed in 10% formalin for 24 h. After
subsequent storage in 70% ethanol, the embryos were
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Table 1. Differential glomerular expression of cytoskeleton-related genes between 4- and 6-week-old Dahl rats and SHR rats
Gene name
Gene
symbol
Chromosomal
location
Fold-difference
in expression Function
Periplakin
Ppl 10q12 4.17 Intermediate filament binding
Moesin Msn Xq31 3.86 Actin filament–membrane cross-linking
Dynamin 1 Dnm1 3p11 3.36 Actin dynamics regulation
Tropomyosin 4 Tpm4 16p14 2.73 Actin binding
Thymoma viral proto-oncogene 1 Akt1 6q32 2.71 Cell projection organization and biogenesis
Supervillin Svil 17q12 2.62 Actin binding
Parvin, alpha Parva 1q33 2.62 Actin cytoskeleton organization and
biogenesis
Plastin 3 (T-isoform) Pls3 Xq14 2.51 Actin filament organization
Tropomyosin 1, alpha Tpm1 8q24 2.23 Actin filament capping
Microtubule-associated protein, RP/EB
family, member 1
Mapre1 3q41 2.2 Regulation of microtubule polymerization
Rho guanine nucleotide exchange factor
(GEF) 17
Arhgef17 1q32 2.1 Actin cytoskeleton organization and
biogenesis
Caldesmon 1 Cald1 4q22 2.1 Actin binding
Signal-regulatory protein alpha Sirpa 3q36 2.04 Actin filament organization
WD repeat domain 44 Wdr44 Xq12 2 Vesicle recycling
Myosin Ib Myo1b 9q22 1.99 Actin binding
Echinoderm microtubule-associated
protein-like 4
Eml4 6q12 1.97 Microtubule stabilization
Actin-related protein 2/3 complex,
subunit 1B
Arpc1b 12p11 1.89 Cytoskeleton organization
Filamin, beta Flnb 15p14 1.87 Actin binding
Myosin IC Myo1c 10q24 1.78 Actin binding
Mitogen-activated protein kinase 1 Map3k1 2q14 1.78 Actin filament polymerization
CAP, adenylate cyclase-associated protein
1 (yeast)
Cap1 5q36 1.73 Actin cytoskeleton organization and
biogenesis
Kinesin light chain 1 Klc1 6q32 1.59 Microtubule motor activity
Src homology 2 domain-containing
transforming protein C1
Shc1 2q34 1.57 Actin cytoskeleton organization and
biogenesis
ARP1 actin-related protein 1 homolog A
(yeast)
Actr1a 1q54 1.55 Cytoskeleton organization
Actin, beta Actb 12p11 1.54 Cytoskeleton organization
A kinase (PRKA) anchor protein 2 Akap2 5q24 1.51 Actin filament organization
Spectrin alpha 1 Spna1 13q24 0.19 Cytoskeleton organization
Polyamine modulated factor 1 binding
protein 1
Pmfbp1 19q12 0.14 Cytoskeleton organization and biogenesis
Table 2. Primer sequences used for RT-PCR analysis
Name (species)
Gene
symbol
mRNA accession
number Forward primer Reverse primer
Dynamin 1 (rat)
Dnm1 NM_080689.4 TTGATGAGAAGGAACTGCGAAGG AAGCGAGGTCAGGAGTGAAGAG
Dynamin 2 (rat) Dnm2 NM_013199.1 TGAAATGCGTGGACCTGGTT CAATGCGTTCGGTCTCCTCT
Cathepsin L (rat) Ctsl NM_013156.2 CAGTGGAAGTCCACACACAGA GTGCTTCCCGTTGCTGTACT
Hypoxanthine
phosphoribosyltransferase 1 (rat)
Hprt1 NM_012583.2 GGCTATAAGTTCTTTGCTGACCTG AACTTTTATGTCCCCCGTTGA
embedded in paraffin, sectioned at 3 μm thickness,
and examined using fluorescence microscopy for the
presence of reabsorption droplets in the proximal tubule
epithelial cells by an investigator who was blinded
with respect to the treatment conditions. The number
of reabsorption droplets in the proximal tubule cells
was counted and compared between groups. The 3 kDa
dextran tracer freely passes the GFB and is subse-
quently reabsorbed by the proximal tubule epithelial
cells. Therefore, reabsorption of this tracer is used as
an indicator of sufficient tubular reabsorption function.
In contrast, the 70 kDa tracer does not readily pass the
GFB under normal conditions and is therefore used as
an indicator of glomerular permeability [16]. The PAN
and dextran injections were performed under anesthesia
with 4% tricaine methanesulfonate.
Human materials
Biopsies from 26 patients with a variety of proteinuric
kidney diseases were obtained from the LUMC tissue
archive. Eight biopsies were from patients with minimal
change disease; three were from patients with focal
segmental glomerulosclerosis; three were from patients
with IgA nephropathy; six were from patients with lupus
nephritis; and six were from patients with diabetic
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Table 3. Patient characteristics
Control DN LN MCD FSGS IgAN
Number of patients (n) 15 6 6 8 5 4
Mean age, years (SD) 54.8 (16.11) 50.2 (19.11) 29.3 (12.15) 31.1 (20.88) 36.2 (7.19) 34.5
Mean serum creatinine, μmol/l (SD) 101.57 (37.95) 140.80 (76.30) 112.80 (39.51) 77.38 (27.77) 112.80 (60.24) 107.5 (34.09)
Proteinuria, g/24 h (SD) 0.14 (0.12) 1.15 (0.82) 2.50 (1.86) 3.56 (3.32) 5.08 (1.84) 4.40 (3.19)
nephropathy. In addition, 16 samples were used as a
control group; these samples consisted of biopsy
material obtained from patients with no evidence
of glomerular pathology whose kidneys were unsuitable
for transplantation due to technical reasons, or from
autopsy tissue. Patient characteristics are summarized
in Table 3. All tissue samples were obtained and handled
in accordance with institutional guidelines and with the
Code of Conduct regarding the responsible use of human
tissues [18].
Immunohistochemistry
The mouse anti-dynamin antibody Hudy 1 (Upstate
Biotechnology, Lake Placid, NY, USA; catalog number
05-319, diluted 1:80) was used to detect dynamin.
Hudy 1 is a monoclonal antibody that recognizes
both dynamin 1 and dynamin 2. Hudy 1 recognizes
the epitope of residues 822–838 within the proline-rich
domain of dynamin. Anti-mouse Envision (Dako Cyto-
motion, Glostrup, Denmark) was used as a secondary
antibody to detect the primary antibody. A rabbit
anti-cathepsin L antibody (Abcam, Cambridge, UK;
ab203028, diluted 1:100) was used to detect cathepsin
L. The results were analyzed by measuring the percent
positive area in the glomeruli using the ImageJ digital
image analysis program. No scarred glomeruli were
included in these analyses.
Statistical analyses
Statistical analyses were performed using SPSS version
23.0 (IBM Corp, Armonk, NY, USA). Levels of mRNA
and protein were compared using one-way ANOVA
(with Dunnett’s post hoc analysis when more than three
groups were compared). Student’s unpaired t-test was
used when two or three groups were compared. Corre-
lation analysis was performed using the Pearson corre-
lation coefficient. Differences with a P value less than
0.05 were considered significant.
Results
Gene expression profiling between Dahl and SHR
rats
First, we investigated differences in the gene expression
between Dahl rats and SHR rats using microarray
analysis. With respect to cytoskeleton-related genes,
we found 28 genes that were differentially regulated
between Dahl rats and SHR rats (Table 1). Of these
28 genes, 26 were significantly upregulated (includ-
ing Dnm1), and two genes (Spna1 and Pmfbp1) were
downregulated.
Glomerular Dnm1 and Dnm2 mRNA – but not
dynamin protein area expression – are increased
in Dahl rats prior to the onset of proteinuria
Next, we measured glomerular dynamin expression
in the Dahl salt-sensitive spontaneously proteinuric
and hypertensive rat model (referred to here as sim-
ply Dahl rats) and the spontaneously hypertensive
rat (SHR). Dahl rats under a low dietary salt intake
developed significant proteinuria beginning at 6 weeks
of age; in contrast, SHR rats did not develop proteinuria,
even at 10 weeks of age (Figure 1A). Consistent with
the spontaneous hypertension phenotype, both strains
developed hypertension to a similar extent beginning at
8 weeks of age (Figure 1B).
As Dnm2 is the ubiquitous and prevalent form of
dynamin, we measured both glomerular Dnm2 and
Dnm1 mRNA levels (Figure 1C,D, respectively). When
analyzing only theDahl group, no significant differences
in glomerular Dnm2 mRNA levels were seen between
weeks 2, 6, 8, and 10. However, these levels were higher
at 4 weeks of age than at all other time points (p< 0.0001
compared with weeks 2, 6, 8, and 10; Figure 1C). In
SHR rats, a significant difference in glomerular Dnm2
levels was foundwhenweek 2was comparedwithweeks
8 and 10 (p< 0.001 and p< 0.01, respectively) and also
between weeks 4 and 8 (p< 0.05, Figure 1C). A simi-
lar analysis of glomerular Dnm1 mRNA levels in Dahl
rats showed a gradual increase from week 2 to week 6,
after which the levels decreased. This difference is sig-
nificant between weeks 6 and 10 (p< 0.05, Figure 1D).
SHR rats showed very low expression of glomerular
Dnm1 mRNA at week 2 which increased slightly, but
not significantly, up until 6 weeks (Figure 1D). None
of the differences in mRNA levels at the different time
points were significant in this group. When compar-
ing dynamin mRNA levels between Dahl and SHR
rats, the level of glomerular Dnm2 mRNA was sig-
nificantly increased in Dahl rats compared with SHR
rats at 2 and 4 weeks of age (Figure 1C, p < 0.05
and p< 0.0001, respectively). GlomerularDnm1mRNA
was significantly higher in Dahl rats than in SHR rats
at 2, 4, and 6 weeks of age (Figure 1D). Interestingly,
the levels of both Dnm1 mRNA and Dnm2 mRNA at
2 weeks of age were higher in Dahl rats than in SHR
rats, which is before the onset of proteinuria (i.e. at
6 weeks of age). Also, when comparing the different age
groups, animals that will become proteinuric (i.e. the
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Figure 1. Glomerular Dnm2 and Dnm1 mRNA levels – but not
dynamin protein levels – are increased in Dahl rats prior to the
onset of proteinuria. (A, B) Summary of urinary albumin excretion
(UAE) (A) and systolic blood pressure (SBP) (B). (C, D) Summary of
glomerular Dnm2 mRNA (C) and Dnm1 mRNA (D). (E, F) Example
images of glomeruli from an SHR rat (E) and a Dahl rat (F) immunos-
tained for dynamin. Similar to the pattern seen in human kidney
sections, dynamin protein was present in podocytes and the tubu-
lar brush border. (G–I) Summary of the percent glomerular positive
area for dynamin protein (G), the percent glomerular positive area
for cathepsin L protein (H), and glomerular cathepsin L (Ctsl) mRNA
(I) in Dahl and SHR rats at the indicated ages. No difference was
seen for either dynamin or cathepsin L percent glomerular positive
area. *p< 0.05 versus the SHR group. The images in E and F were
taken at the same magnification. Scale bar= 50 μm.
Dahl rats) have an increase in glomerular Dnm2 expres-
sion prior to the onset of proteinuria. When compar-
ing PCR Ct values, Dnm2 mRNA levels were found to
be more than ten times higher than Dnm1 levels. With
respect to dynamin protein levels, immunohistochem-
istry revealed that the protein was present at the tubular
brush border and in podocytes in both Dahl and SHR
rats (Figure 1E,F) at similar levels at both 4 and 6 weeks
of age (i.e. after Dahl rats develop proteinuria) (p= 0.6,
Figure 1G).
Ctsl mRNA levels – but not protein area
expression – are higher in Dahl rats than in SHR
rats
Cathepsin L, encoded by the Ctsl gene, is an enzyme
that cleaves dynamin [3]. We therefore measured the
expression of cathepsin L in the glomeruli of Dahl and
SHR rats using RT-PCR (Figure 1I). We found that Ctsl
mRNA levels were significantly higher in the glomeruli
of Dahl rats compared with SHR, ranging from 1.3-fold
to 1.7-fold higher, at all ages tested (p< 0.01). Immuno-
histochemistry revealed that there was no difference
between Dahl and SHR rats in the glomerular cathepsin
L-positive area (p= 0.11 and p= 0.70 at 4 and 6 weeks
of age, respectively; Figure 1H).
Knocking down dynamin translation causes
proteinuria
Next, we knocked down dynamin expression
in zebrafish embryos using morpholino injection
followed by injection of a mixture of 3 and 70 kDa
dextran tracers (Figure 2A,B). As a positive control
for inducing proteinuria, a separate group of embryos
received an injection of puromycin aminonucleoside
(PAN). We then quantified the reabsorption of dextran
droplets. Our analysis revealed that the mean number
of 3 kDa dextran droplets was similar between control
zebrafish (which received an injection of a scram-
bled morpholino), dynamin-knockdown zebrafish, and
PAN-injected zebrafish (p= 0.96, Figure 2C), indicat-
ing that knockdown of dynamin in this model does not
significantly affect tubular reabsorption. In contrast, the
dynamin-knockdown zebrafish had significantly more
reabsorption of 70 kDa droplets compared with control
zebrafish (p< 0.0001, Figure 2D), indicating that loss
of dynamin increases glomerular permeability, as also
shown in the zebrafish model by Schiffer et al [7].
Dynamin protein levels are increased in the
glomeruli of patients with proteinuria
Finally, we examined the expression of dynamin in the
kidneys of patients with proteinuria (Figure 3A–D).
Biopsies were obtained from patients with pro-
teinuric kidney disease and control subjects, and
stained by immunohistochemistry for the presence
of dynamin. Positive staining was found primarily in
podocytes, at the tubular epithelial brush border, and
in endothelial cells of larger vessels. When individual
disease groups were compared with the controls, the
glomeruli of patients with minimal change disease
(MCD) and lupus nephritis (LN) had a significantly
higher dynamin-positive area percentage (p= 0.03
and p= 0.04, respectively; Figure 3I). No scarred
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Figure 2. Blocking the translation of dnm mRNA in zebrafish embryos causes proteinuria. Wild-type zebrafish embryos were injected with
an anti-dnmmorpholino or a scrambled control morpholino, followed by a mixture of 3 and 70 kDa dextran molecules. (A, B) Representative
fluorescence images of the proximal tubule epithelial cells (circled structure) in a dynamin-knockdown zebrafish embryo. (C, D) The number
of fluorescent droplets below the luminal surface was counted in control embryos, dynamin-knockdown embryos, and wild-type embryos
injected with puromycin aminonucleoside (PAN) as a positive control for increased glomerular permeability. *p< 0.05 versus control. A
digital high-pass filter has been placed over panels A and B to enhance the contrast between reabsorption droplets and the surrounding
tissue. The images in A and B were taken at the same magnification. Scale bar= 10 μm.
glomeruli were included in these analyses. No correla-
tion was found between proteinuria levels and dynamin
expression levels (Figure 3K).
Cathepsin L protein levels are also increased in the
glomeruli of patients with proteinuria
The same cohort was also stained by immunohistochem-
istry for the presence of cathepsin L (Figure 3E–H).
We found a significantly higher glomerular cathepsin
L-positive area percentage in patients with MCD, LN,
and IgA nephropathy (IgAN; p< 0.0001 compared with
controls in all three groups, Figure 3J). A positive corre-
lation was found between the glomerular positive area
percentages for dynamin and cathepsin L (r= 0.928,
p= 0.0075).
Discussion
Here, we have investigated dynamin expression under
proteinuric conditions in both patients and rats. In
addition, we examined whether dynamin is involved
in glomerular proteinuria, tubular proteinuria, or both.
We found a significant increase in the glomerular levels
ofDnm2 andDnm1mRNA inDahl rats prior to the onset
of albuminuria. We also showed that knocking down
dynamin translation results in proteinuria in a zebrafish
embryo model. Lastly, we found that the glomerular lev-
els of dynamin and cathepsin L protein are significantly
increased in patients with proteinuric kidney disease.
Our finding of increased dynamin protein and Dnm1
and Dnm2 mRNA levels in proteinuric disease, com-
bined with the results of Soda et al [4] showing that
dynamin knock out results in proteinuria, leads to the
following two hypotheses on dynamin’s role in GFB
integrity. First, a minimum level of dynamin may be
required for adequate GFB integrity; thus, if this level
is not reached, GFB integrity is lost. Second, when the
GFB is under stress, dynamin may be upregulated in an
attempt to maintain or restore GFB integrity. We pre-
viously studied the expression of proteins required for
proper GFB function in patients with acquired protein-
uria and found changes that suggest a compensatory
mechanism [19]. Thus, disease progression may occur
when this compensatory mechanism becomes saturated
or exhausted.
In Dahl rats, which spontaneously develop protein-
uria, we found that the levels ofDnm1 andDnm2mRNA
are increased prior to the onset of proteinuria, a symptom
that manifests only when protein is present in excreted
urine. Proteinuria occurs when proteins pass through
the GFB and are not sufficiently reabsorbed by the
tubular system, due to either saturation or malfunction
of the tubular reabsorption process. Thus, the increase in
glomerular Dnm1 and Dnm2 mRNA levels prior to the
onset of proteinuria might reflect a compensatory mech-
anism in response to an early, presymptomatic increase
in GFB permeability that does not yet lead to actual
proteinuria. However, as proteinuric disease progresses,
this compensatory system can become exhausted,
thereby failing to prevent the onset of proteinuria.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 3. Glomerular dynamin protein levels are increased in human proteinuric kidneys. (A–H) Representative images of glomeruli
immunostained for dynamin (A–D) or cathepsin L (E–H) in a healthy control subject (A, E), a patient with diabetic nephropathy (B, F),
a patient with lupus nephritis (C, G), and a patient with minimal change disease (D, H). (I, J) Summary of the percent glomerular positive
area for dynamin (I) and cathepsin L (J) in patients with the indicated proteinuric kidney diseases. Dynamin protein expression is significantly
higher in LN and MCD compared with control; *p< 0.05 versus control. Cathepsin L protein expression is significantly higher in LN, MCD, and
IgAN compared with control; *p< 0.05 versus control. (K) Summary of the proteinuria data of the different patient groups. No correlation was
found between the level of proteinuria and dynamin staining. Patients with MCD, FSGS, and IgAN all had significantly more proteinuria than
control patients; **p< 0.01, ***p< 0.001. MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy;
LN, lupus nephritis; DN, diabetic nephropathy. All images were taken at the same magnification. Scale bar= 50 μm.
This hypothetical process is depicted schematically
in Figure 4.
Interestingly, we found that while animals that will
become proteinuric (Dahl rats) express both more
glomerular Dnm2 and Dnm1 mRNA before the onset
of proteinuria, this does not result in an increase in
dynamin protein. However, since dynamin is a regu-
latory GTPase, it is not necessary to have an increase
in protein level to have an altered intracellular activ-
ity. Also, cathepsin L-mediated cleavage of dynamin
may be increased and cause a decrease in dynamin
protein staining [3]. In humans, we found that there is
indeed an increase in glomerular cathepsin L protein
which directly and strongly correlated with glomerular
dynamin protein levels, as also observed by Sever et al
[3]. Cleavage of dynamin by cytosolic L generates a
40 kDa N-terminal fragment of dynamin. As the used
antibody recognizes an epitope of residues 822–838 of
dynamin, these fragments were not identifiable in the
immunohistochemistry experiments performed in this
study. In our study, we found significantly higher levels
of Ctsl mRNA in Dahl rats at all ages investigated,
suggesting that in this rat model both the transcription
and the post-translational cleavage of dynamin are
increased. Although the Hudy 1 antibody used does not
distinguish between DNM1 and DNM2 proteins, the
higher Dnm2 mRNA levels suggest that Dnm2 is the
more prevalent type of dynamin, as also reported by
others [4].
We found that the glomerular levels of dynamin pro-
tein were increased primarily in patients with minimal
change disease (MCD) and lupus nephritis. Schiffer et al
recently proposed that dynamin’s principal role in main-
taining podocyte structure and preventing proteinuria is
independent of the underlying disease pathogenesis [7]
Our results are consistent with this notion, given that
lupus nephritis is considered to be immunological in ori-
gin, whereas MCD is not [20,21].
Sever et al previously reported that the levels of CTSL
mRNA were increased in the glomeruli of patients with
acquired proteinuric disease [3]. Notably, the levels
of CTSL mRNA expression were increased in patients
with focal segmental glomerulosclerosis (FSGS) and in
patients with diabetic nephropathy, but not in patients
withMCD. Interestingly, we found that dynamin expres-
sion was significantly increased in patients with MCD,
but not in patients with FSGS or diabetic nephropathy;
Sever et al did not measure CTSL mRNA in patients
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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Figure 4. Increased dynamin expression precedes proteinuria. Flow chart illustrating the proposed compensatory mechanism in response
to impaired integrity of the glomerular filtration barrier, in which increased dynamin expression precedes proteinuria. After damage to
the glomerular filtration barrier, DNM1 and DNM2 are upregulated, leading to increased levels of DNM1 and DNM2 mRNA. Whether this
increase results in increased levels of dynamin protein depends on the oligomerization status of dynamin and the activity of cathepsin
L, which selectively cleaves non-oligomerized dynamin [3]. If the total amount of dynamin is sufficient, the glomerular filtration barrier
remains intact, preventing the onset of proteinuria. However, if dynamin levels are insufficient – and/or if this compensatory response is
exhausted – proteinuria develops. The suggested mechanisms of cytoskeletal architecture maintenance and nephrin turnover have been
reported by others [3–5,7,8,22–24].
with lupus nephritis. In our study, we found signifi-
cantly more cathepsin L protein in the glomeruli of
patients with MCD, lupus nephritis, and IgA nephropa-
thy. Although we did see an increase in the glomerular
cathepsin L-positive area percentage in DN patients, as
also reported by Sever et al, this increase was not statis-
tically significant.
Thus, taken together, these results suggest that
in human proteinuric disease, the interplay between
cathepsin L and dynamin is part of a regulatory system
influenced by proteinuria, as proposed previously [3].
Dynamin’s protective effect on the GFB could be
effected through its role in nephrin turnover, as sug-
gested by other groups [4,22–24]. Nephrin (encoded
in rats by the Nphs1 gene) is a core component of the
glomerular slit diaphragm [25]. In podocytes, nephrin
is internalized by clathrin-mediated endocytosis and
clathrin-independent raft-mediated endocytosis, both of
which are dynamin-dependent processes [23]. We pre-
viously reported that Nphs1 mRNA levels are increased
significantly in Dahl rats by 10 weeks of age, although
the pattern of nephrin protein is focal and segmental
rather than linear, and effacement of the podocyte foot
process occurs [26]. In this study, we found that the
levels ofDnm1 andDnm2mRNA are significantly lower
at 10 weeks of age compared with younger ages. These
results suggest that the relative decrease in Dnm1 and
Dnm2mRNA in Dahl rats at later ages results in a loss of
sufficient nephrin turnover, which then leads to reduced
protection against podocyte pathology.
Dynamin also directly interacts with the actin
cytoskeleton, as shown by others [3,5,7,8]. Consis-
tent with this structural role, our microarray analysis
revealed additional evidence that the cytoskeletal archi-
tecture is disrupted in Dahl rats, given the differential
regulation of cytoskeleton-related genes. Further stud-
ies will likely provide new insight into how the actin
cytoskeleton is regulated under proteinuric conditions.
In conclusion, our results provide evidence that
dynamin expression is increased in human protein-
uric disease. Moreover, we propose that a minimum
level of dynamin is required for GFB integrity, and
increases in Dnm1 and Dnm2 mRNA are part of a
compensatory mechanism that supports GFB integrity
under stressful conditions. Given that this mechanism
seems to play a role in patients with proteinuric kidney
disease, dynamin may represent a promising target for
therapeutic intervention.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018
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